---
document_datetime: 2023-09-21 21:52:02
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/orfadin-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: orfadin-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 11.3186981
conversion_datetime: 2025-12-30 02:47:24.246097
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Orfadin

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0082              | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 13/04/2023                          |                                             | SmPC                             |           |
| IB/0081              | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting                                                       | 04/01/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0080            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/11/2022 | n/a |                                   |
| PSUSA/2169/ 202202 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 29/09/2022 | n/a | PRAC Recommendation - maintenance |
| IA/0078/G          | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a | 18/02/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                    | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                    |            |            |             |                                                            |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------|
| PSUSA/2169/ 202102 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                                                                                                                                                                                                                                                                                 | 30/09/2021 | n/a        |             | PRAC Recommendation - maintenance                          |
| IA/0077            | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                             | 25/08/2021 | n/a        |             |                                                            |
| II/0075            | B.II.b.5.d - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of an in-process test which may have a significant effect on the overall quality of the finished product                                                                                                                                                                                                                                                             | 28/05/2021 | n/a        |             |                                                            |
| II/0074            | Submission of the final report from study Sobi.NTBC- 005 listed as a category 3 study in the RMP. This is a non-interventional Post Authorization Safety Study (PASS) to evaluate long-term safety of Orfadin treatment in hypertyrosinemia type 1 (HT-1) patients in standard clinical care. The RMP version 5.5 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 11/02/2021 | n/a        |             |                                                            |
| II/0071            | Extension of indication to include treatment of adult                                                                                                                                                                                                                                                                                                                                                                                                                                    | 17/09/2020 | 22/10/2020 | SmPC and PL | Please refer to Scientific Discussion 'Orfadin-H-C-000555- |

<div style=\"page-break-after: always\"></div>

|                    | patients with alkaptonuria (AKU) for Orfadin; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1 and 10 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.2 of the RMP has also been submitted accordingly and includes an update in accordance with GVP Module V Revision 2. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                     |            |     | II-71'                            |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/2169/ 202002 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 01/10/2020 | n/a | PRAC Recommendation - maintenance |
| IA/0072/G          | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates | 08/05/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                    | exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                 |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IAIN/0070          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/12/2019 | 22/10/2020 | Annex II and PL |                                   |
| PSUSA/2169/ 201902 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/09/2019 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0068/G        | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is | 02/04/2019 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|                    | not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0067            | Update of sections 4.4, 4.5 and 5.2 to add a warning on interaction with medicinal products with a narrow therapeutic window metabolized through CYP2C9 and information based on in vitro and in vivo drug drug interaction studies investigating effects of nitisinone on cytochromes CYP2C9,CYP2D6, CYP2E1, OAT1, OAT3, CYP2D6, CYP1A2, CYP2B6, CYP3A4/5, P-gp, BCRP, OATP1B1, OATP1B3 or OCT2-mediated transport. This update is following PRAC conclusions on PSUSA (EMEA/H/C/PSUSA/00002169/201802) adopted on 6 September 2018. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 07/03/2019 | 05/12/2019 | SmPC and PL            | New information on in vivo and in vitro interactions were added to the Product Information. This included a warning that nitisinone, as a moderate inhibitor of CYP2C9, may result in increased plasma concentrations of co- administered medicinal products metabolized primarily via CYP2C9. Nitisinone treated patients who are concomitantly treated with medicinal products with a narrow therapeutic window metabolized through CYP2C9, such as warfarin and phenytoin, should be monitored for toxicity of the co- administered medicinal products. |
| IB/0066/G          | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                              | 19/12/2018 | 05/12/2019 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/2169/ 201802 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/09/2018 | 20/11/2018 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2169/201802.                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0065/G   | This was an application for a group of variations.   | 13/07/2018   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|                    | Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                                  |            |     |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0063            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                               | 16/10/2017 | n/a |                                   |
| PSUSA/2169/ 201702 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/09/2017 | n/a | PRAC Recommendation - maintenance |
| IA/0061            | B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                   | 24/04/2017 | n/a |                                   |
| IA/0060/G          | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits B.I.c.2.b - Change in the specification parameters | 17/03/2017 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method B.I.c.2.c - Change in the specification parameters and/or limits of the immediate packaging of the AS - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0057 | Update of sections 4.2 and 5.1 of the SmPC in order to amend the dosing frequency further to the results of a clinical pharmacology study NTBC-003. The Package Leaflet and Risk Management Plan are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 15/12/2016 | 26/01/2017 | SmPC and PL | In view of results from a clinical pharmacology study, the Product Information was updated with regards to the dosing frequency. The following revisions were introduced in section 3 of the Package Leaflet (How to take Orfadin) to update the information on dosing (new text bold, old text in strikethrough mode): The recommended total daily dose is 1 mg/ kg body weight taken once daily divided in 2 doses administered orally. Your doctor will adjust the dose individually. It is recommended to administer the dose once daily, administered orally. However, due to the limited data in patients with body weight <20 kg, it is recommended to |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                                  | divide the total daily dose into two daily administrations in this patient population.                                                                                                                                                                                                                                                                                                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0056   | Update of section 5.1 of the SmPC in order to present the efficacy data based on a complementary analysis of the pivotal study for Orfadin (NTBC study). In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the Product Information in line with the latest QRD template version 10. The requested variation proposed amendments to the Summary of Product Characteristics, Labelling and Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 15/12/2016 | 26/01/2017 | SmPC, Annex II, Labelling and PL | In view of a complementary analysis of the pivotal NTBC study as well as data from a study used as a historical control (van Spronsen et al., 1994) the tables presenting survival probabilities were updated in section 5.1 of the SmPC. In addition, further details on the reduction of risk of development of hepatocellular carcinoma were included in a tabular format in section 5.1 of the SmPC. |
| IA/0059/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                  | 22/11/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0058   | Update of section 5.3 of the SmPC in order to add a statement that carcinogenic potential was not shown in a 26-week carcinogenicity study                                                                                                                                                                                                                                                                                                                                                                                                                    | 15/09/2016 | 26/01/2017 | SmPC                             | The following change to the SmPC Section 5.3 is introduced with this variation: Nitisinone did not show carcinogenic potential in a 26-week                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                    | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                            |            |     | carcinogenicity study in transgenic mice (TgrasH2).   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------|
| PSUSA/2169/ 201602 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                                     | 02/09/2016 | n/a | PRAC Recommendation - maintenance                     |
| IB/0055            | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                   | 09/06/2016 | n/a |                                                       |
| IA/0053            | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                      | 25/05/2016 | n/a |                                                       |
| IA/0052            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 04/02/2016 | n/a |                                                       |
| IB/0051            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                 | 05/01/2016 | n/a |                                                       |
| IA/0050/G          | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                              | 16/11/2015 | n/a |                                                       |

<div style=\"page-break-after: always\"></div>

|                    | B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                              |            |            |                                  |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IB/0049            | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                             | 26/10/2015 | n/a        |                                  |                                   |
| IA/0048            | B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer | 21/10/2015 | n/a        |                                  |                                   |
| PSUSA/2169/ 201502 | Periodic Safety Update EU Single assessment - nitisinone                                                                                                                                                                    | 10/09/2015 | n/a        |                                  | PRAC Recommendation - maintenance |
| X/0041             | To add a new pharmaceutical form: oral suspension Annex I_2.(d) Change or addition of a new pharmaceutical form                                                                                                             | 23/04/2015 | 19/06/2015 | SmPC, Annex II, Labelling and PL |                                   |
| X/0042             | To add a new strength 20 mg capsule, hard. Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                       | 26/02/2015 | 05/05/2015 | SmPC, Labelling and PL           |                                   |
| IA/0046            | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                         | 20/11/2014 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

| PSUV/0044   | Periodic Safety Update                                                                                                                                                                                                                                                  | 11/09/2014   | n/a        |                        | PRAC Recommendation - maintenance   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IB/0045     | To reduce in-use storage time of the finished product from 'a single period of 3 months' to ' a single period of 2 months' at a temperature not above 25Â°C. B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale | 25/07/2014   | 05/05/2015 | SmPC, Labelling and PL |                                     |
| IAIN/0043   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                         | 08/04/2014   | n/a        |                        |                                     |
| IB/0039     | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                  | 25/09/2013   | n/a        |                        |                                     |
| IAIN/0040   | B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings                                                                             | 19/07/2013   | 27/06/2014 | SmPC and PL            |                                     |
| IA/0038     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                            | 06/12/2012   | n/a        |                        |                                     |
| IA/0037     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                      | 15/10/2012   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

|         | procedure                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |           |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IA/0036 | B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                    | 10/10/2012 | n/a |           |
| IB/0034 | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                 | 23/07/2012 | n/a |           |
| IB/0031 | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                           | 02/03/2012 | n/a |           |
|         | This was an application for a group of variations. B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer | 27/02/2012 | n/a | IA/0033/G |
| IA/0032 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                             | 31/01/2012 | n/a |           |
| IA/0030 | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                                      | 30/11/2011 | n/a |           |

<div style=\"page-break-after: always\"></div>

| IB/0029   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                      | 15/06/2011   | n/a   |                                  |          |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------------------|----------|
| IB/0028   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                | 15/06/2011   | n/a   |                                  |          |
| IA/0027/G | This was an application for a group of variations. B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate already approved manufacturer | 28/02/2011   | n/a   |                                  | from an  |
| IA/0026/G | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished including quality control sites (excluding              | 26/10/2010   | n/a   | SmPC, Annex II, Labelling and PL | product, |

<div style=\"page-break-after: always\"></div>

|         | manufacturer for batch release)                                                                  |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0023  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 29/07/2010 | n/a        | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| R/0021  | Renewal of the marketing authorisation.                                                          | 19/11/2009 | 19/01/2010 | SmPC, Annex II, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP was of the opinion that the quality, safety and efficacy of Orfadin continue to be adequately and sufficiently demonstrated. Orfadin remains the only therapeutic treatment so far available for the treatment of the rare disease tyrosinemia type 1 and the risk/benefit of Orfadin in the treatment of the approved indication continues to be favourable. The CHMP was of the opinion that the renewal could be |
| IA/0022 | IA_13_a_Change in test proc. for active substance - minor change                                 | 11/01/2010 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| S/0019  | ANNUAL REASSESSMENT                                                                              | 25/06/2009 | 21/09/2009 | SmPC, Annex II and PL            | \"The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable. The CHMP considered that, as all specific obligations have been fulfilled, there are no remaining grounds for the Marketing Authorisations to remain under exceptional circumstances.\"                                                                                               |
| IA/0020 | IA_05_Change in the name and/or address of a                                                     | 27/07/2009 | n/a        | Annex II and                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | manufacturer of the finished product                                                           |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0018 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure | 14/10/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0017 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure | 14/10/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0016 | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure | 14/10/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IA/0015 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer            | 14/10/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| S/0014  | Annual re-assessment.                                                                          | 26/06/2008 | n/a | The CHMP having reviewed the evidence of compliance with the Specific Obligations submitted by the MAH and having re-assessed the benefit/risk profile of Orfadin, considered that no update of the Community Marketing Authorisation was necessary. The overall benefit/risk of Orfadin in the treatment of the approved indication remains unchanged. The CHMP agreed that the Marketing Authorisation should be kept under exceptional circumstances. |
| IB/0013 | IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)       | 29/04/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0012 | IB_10_Minor change in the manufacturing process of the active substance                        | 29/04/2008 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0011   | IB_17_a_Change in re-test period of the active substance                                         | 29/04/2008   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|--------------------------------------------------------------------------------------------------|--------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0010   | IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening      | 29/04/2008   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0009   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer              | 19/02/2008   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| S/0008    | Annual re-assessment.                                                                            | 21/06/2007   | 23/08/2007 | Annex II | The CHMP having reviewed the evidence of compliance with the Specific Obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile of Orfadin, concluded that, overall, the benefit/risk ratio for the medicinal product remains unchanged. The CHMP also considered that the Specific Obligation to further analyse the remaining histological samples from the 12 and 6 month rodent toxicity studies can be considered fulfilled based on the final study report submitted in June 2006. The CHMP considered that the Marketing Authorisation should be kept under exceptional circumstances and agreed on a revised list of Specific Obligations. |
| N/0007    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 23/01/2007   | n/a        | PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0006   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer              | 24/11/2006   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| S/0003   | Annual re-assessment.                                                                                                                                                                                                | 28/06/2006   | 28/08/2006   | SmPC, Annex II, Labelling and PL   | The CHMP, having reviewed the evidence of compliance with the Specific Obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile of Orfadin, concluded that, overall, the benefit/risk ratio for the medicinal product remains unchanged. The CHMP considered that the marketing authorisation should be kept under exceptional circumstances, and agreed on a revised list of Specific Obligations.                                                                                                            |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0005  | IA_39_Change/addition of imprints, bossing or other markings                                                                                                                                                         | 07/06/2006   | n/a          | SmPC and PL                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IA/0004  | IA_38_a_Change in test procedure of finished product - minor change to approved test procedure                                                                                                                       | 07/06/2006   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0002  | Update of section 4.4 of the Summary of Product Characteristics to include a warning recommending monitoring visits every 6 months or shorter intervals in case of AEs. Update of Summary of Product Characteristics | 23/03/2006   | 18/04/2006   | SmPC                               | Following the evaluation of the Post Marketing Surveillance (PMS) programme to monitor hepatic, renal, haematological, neurological and ophthalmic status on all patients treated with the product, the CHMP was of the opinion that the follow-up visits should take place at shorter intervals. Therefore, the CHMP requested to the MAH to include a warning in section 4.4 of the SPC recommending monitoring visits every 6 months or shorter intervals in case of AEs. The MAH submitted this type II variation to update the SPC as requested by the CHMP. |
| IA/0001  | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                  | 08/09/2005   | n/a          |                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |